Geron news from FierceBioResearcher

The news that the FDA had put a ‘clinical hold' on Geron's plans to launch the first U.S. clinical trial of a stem cell therapy is attracting considerable scrutiny from researchers. The

Read more...

In a first, Geron made headlines at the BIO CEO conference in New York with its announcement that it could begin its first human trials using embryonic stem cells to treat spinal cord injuries as Read more...

Stem Cell Research Researchers at Geron and Advanced Cell Technology are jockeying to begin the first human clinical trials of embryonic stem cell therapies. Geron plans to file for regulatory Read more...

Researchers from Geron and the University of Washington have completed new animal studies that offer fresh evidence Read more...

Stem Cell Research Critics maintain that Geron's repeated assertion that it is a year away from beginning trials on its stem cell program serves as an example of research Read more...

Stem Cell Research

Geron announced that its embryonic stem cell therapy for spinal cord injuries is not attacked by the immune system, a finding that could lower or eliminate the need for immune-suppressing drugs for patients. Report

In what is seen as an important step toward a cure for Parkinson's, researchers have injected human stem cells into monkeys …

Read more...

Stem Cell Research

Using stem cells extracted from umbilical cords, researchers at the University of Texas Medical Branch teamed with scientists in the UK were able to coax them to produce insulin, offering an approach to curing diabetes. Dr. Randall Urban, who led the study, said that they were on the first rung of the ladder. The news follows a report from last week that Geron had used embryonic stem cells to create new …

Read more...

Geron stock got a big boost just days ago when researchers announced that they had coaxed embryonic stem cells into clusters that produced insulin in response to elevated levels of glucose. The work points to a potential cure for Type 1 diabetes, which had investors cheering up its stock by about 10 percent. Some analysts note that the company has been the subject of a considerable amount of press attention, which hasn't hurt its stock price.

"These studies show that the islet-like …

Read more...

Stem cell research

Geron CEO Tom Okarma used BIO 2007 as a setting to tout upcoming clinical trials of an embryonic stem cell therapy for spinal cord injuries. "The world's spotlight will be on this trial," he maintains, which some observers see as a possible blessing or a curse. Report

UC Irvine neurobiologist Hans Keirstead and his research team have launched a …

Read more...

Stem cells take center stage
The Stem Cell Summit in San Diego this week (below) is providing some solid data to suggest that a small wave of new therapies will be seeking FDA approval in the near future. It's clear that the …

Read more...